Supplementary information for:

Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay

Rafael R. G. Machado¹f, Talita Glaser²f, Danielle B. Araujo¹, Lyvia Lintzmaier Petiz², Danielle B. L. Oliveira¹, Giuliana S. Durigon³, Alessandra L. Leal⁴, João Renato R. Pinho⁵, Luis Carlos S. Ferreira^{1,6}, Henning Ulrich²f, Edison L. Durigon^{1,6}f and Cristiane R. Guzzo¹f

- ¹ Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
- ² Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
- ³ Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil.
- ⁴ Gaspar Vianna Clinic Hospital Foundation, Belém, Brazil.
- ⁵ Hospital Israelita Albert Einstein, São Paulo, Brazil; LIM-03, Central Laboratories Division, Clinics Hospital, São Paulo School of Medicine, University of São Paulo, São Paulo, Brazil; LIM-07, Institute of Tropical Medicine, Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil.
- ⁶Scientific Platform Pasteur USP, São Paulo, Brazil.

f Both authors contributed equally

* Corresponding author E-mail: eldurigo@usp.br E-mail: crisguzzo@usp.br E-mail: henning@iq.usp.br **Website development.** The website was developed by MAXXIDATA, a partner company, and the questions were divided in three blocks, all of them available in a logged area: [1] Clinical Case; [2] Treatment; [3] Results (**Figure S1**). The goal is to have this form filled after the treatment is finished, and final results are already available. In the clinical case block, the questions are related to the initial state of the patient, with no personal identification. Below are the questions in the website, for each block:

- 1. Questions for [1] clinical case block: (1.a). Is positive tested to COVID-19?; (1.b) Days since 1st symptoms to treatment, (1.c). Patient was intubated (yes or no); (1.d). Severity of this case (Asymptomatic, Mild or Severe); (1.e) Gender of the patient; (1.f) Initials or your own internal patient ID (this is for their internal control, and it is asked they should not identify the patient); (1.g) Data of birth; (h). Did the patient have any comorbid?
- 2. Questions for [2] treatment block: (2.a). Type of application (Puff, Inhaler, Nebulizer or other); (2.b) Hypertonic concentration; (2.c) Volume in mL; (2.c) Application frequency (every how many hours); (2.d) What else did you use? (chloroquine, azithromycin, hydroxychloroquine and/or other).
- 3. Questions for [3] Results block: (3.a). Treatment outcome: (from 0% to 100%); (3.b) After how many days did you see this result? (3.c) Area for the user to add comments about the case.




Figure S1: The website <u>www.icbcorona.com</u>. Physicians can input and share their observations of clinical cases in which patients were treated with hypertonic solution (inhalation with 1,5% NaCl or greater). The Login (**A**), Clinical Case (**B**), Treatment (**C**), and Results blocks (**D**) are shown.